Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany

Augustin, Matthias; Radtke, Marc Alexander; Engen, A van; Ruedig, Cornelia; Lapp, Christina; Moehling, Ulrich

doi:10.1111/j.1610-0387.2008.06919.x

Cited by 12 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It can therefore be expected that the use of biologics, including UST, will continue to increase with the use of conventional therapies. This trend is currently observed in many countries [37] and believed to result from increased awareness among dermatologists of psoriasis as a significant medical condition that strongly impacts the quality of life and the availability of guidelines and concepts on treatment goals, which support a consequent treatment of affected patients [38]. …”

Section: Five-year Viewmentioning

confidence: 99%

Ustekinumab for the treatment of plaque psoriasis

Reich¹

2009

Expert Review of Dermatology

View full text Add to dashboard Cite

Recent advances in the understanding of disease pathways in psoriasis indicate an important role of IL-23. Ustekinumab is a first-in-class, fully human IgG1 k monoclonal antibody that binds with high specificity to the p40 subunit of IL-12 and IL-23. It is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who failed, are contraindicated to, or intolerant to other systemic therapies. In Phase III studies, ustekinumab significantly improved symptoms of plaque psoriasis by week 12 (psoriasis area and severity index 75 response 66-76%) versus placebo (3-4%; p < 0.0001 for all comparisons versus placebo), and showed continued efficacy through week 76 with every 12-week dosing. Ustekinumab was well tolerated: the incidence of adverse events leading to withdrawal of study medication was less than or equal to 2% across treatment groups. Extended exposure was not found to be associated with lymphocyte depletion or cumulative toxicity. Keywords: anti-IL-12p40 mAb • biologic therapy • CNTO 1275 • IL-12 • IL-23 • plaque psoriasis • ustekinumab Ustekinumab for the treatment of plaque psoriasis Expert

show abstract

Section: Five-year Viewmentioning

confidence: 99%

Ustekinumab for the treatment of plaque psoriasis

Reich¹

2009

Expert Review of Dermatology

View full text Add to dashboard Cite

show abstract

“…According to the 18 studies where we found a definite or potential impact of uncertain variables or assumptions on the final conclusions, the key drivers included (1) the costs of the medication or phototherapy itself, or related assumptions such as dosage, a treatment-free response period, average wholesale price, and weight and waste of excess medications [21,24,27,34,40,43,46,50,51,61,62,71]; (2) the values of efficacy measures, which include PASI response rate, DLQI response rate (a minimally important difference [MID]), clearing rate, response rate achieved in re-treatment [23,26,27,34,40,46,59,61], and the choice of efficacy measures, PASI 75 or DLQI MID [34]; (3) utility values, which comprised of those with different disease severity levels or PASI response health states, baseline utility values, and utility ratings for side effects, or being on the waiting list [22,26,51,57,67]; (4) hospitalization assumptions for non-responders [24,62,67]; (5) considering lost productivity during hospitalization [62]; and (6) different time horizons [40]. …”

Section: Within the Studymentioning

confidence: 99%

Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis

Zhang

Islam

et al. 2014

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…Bereits in 2009 zeigten Augustin et al [3], dass das Kombinationspräparat (Bet/Cal) effektiver und kostengünstiger sei im Vergleich zu den Einzelsubstanzen oder Tacalcitol allein. Wie sich der konsequente Erstlinieneinsatz auf das entsprechende Budget der einzelnen Praxen auswirkt, wird sich zeigen.…”

Section: Transfer In Die Praxis Von Dr Sandra Philipp (Oranienburg)unclassified

Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad

Philipp¹

2019

Kompass Dermatol

View full text Add to dashboard Cite

Die topische Therapie besitzt auch im Zeitalter der Biologika und small molecules einen hohen Stellenwert in der Psoriasistherapie, sei es zur Behandlung milder Formen der Psoriasis oder unterstützend bei mittelschweren bis schweren Formen. Neben der Wahl geeigneter Wirkstoffe ist auch die Galenik von Bedeutung, um die Therapie zu optimieren. Der hier vorgestellte Behandlungspfad wurde im Rahmen der PsoNet-Sprecherkonferenz entwickelt und von den Teilnehmern der nationalen Versorgungskonferenz Psoriasis bestätigt. Er beinhaltet die aktuellen Therapieoptionen und stellt diese in einer Grafik dar. Als Goldstandard wird in der Initialtherapie der Plaque-Psoriasis die Fixkombination aus Calcipotriol 50 µg/g und Betamethason-Diproprionat 0,5 mg/g 1 mal täglich über 4 - 8 Wochen empfohlen. Am effektivsten ist der Schaum, jedoch sollte bei der Wahl der Grundlage auch die Patientenpräferenz einbezogen werden. Zur Erhaltungstherapie wird eine 1 - 2 mal wöchentliche (proaktive) Anwendung empfohlen. In zweiter Linie können Vitamin D Analoga und topische Steroide auch als Monotherapien zum Einsatz kommen. Zusätzlich werden spezifische Empfehlungen für besondere Therapiesituationen (Psoriasis inversa, Kopfpsoriasis, palmoplantare Psoriasis) gegeben. Auf die Festlegung von Therapiezielen wird spezieller Wert gelegt. Eine begleitende Basistherapie wird als selbstverständlich vorausgesetzt. Neue topische Wirkstoffe sind in der Pipeline.

show abstract

Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany

Abstract: The treatment of mild to moderate psoriasis with a fixed calcipotriol/betamethasone combination is a more cost-effective treatment than a treatment with the single agents or tacalcitol monotherapy.

Cited by 12 publications

References 25 publications

Ustekinumab for the treatment of plaque psoriasis

Ustekinumab for the treatment of plaque psoriasis

Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis

Topische Therapie bei Psoriasis vulgaris - ein Behandlungspfad

Contact Info

Product

Resources

About